SLC6A4 and colorectal carcinoma: The SERT inhibitor citalopram (1 μM) did not influence the CRC for 5-HT in endothelium-intact hPAs, but enhanced the potency of 5-HT in endothelium-denuded preparations (for pEC50 values, see Table 1).